At a glance
- Originator Jiangsu Hengrui Medicine Co.; Shanghai Institute of Materia Medica
- Developer Shanghai Institute of Materia Medica
- Class Antineoplastics; Indoles; Morpholines; Pyrroles; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 21 Apr 2022 Discontinued - Phase-I for Solid tumours in China (PO) (Jiangsu Hengrui Medicine pipeline, April 2022)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in China (PO, Tablet)
- 20 Dec 2012 Jiangsu Hengrui Medicine Co. terminates Phase-I trial in Solid tumours in China (NCT01416623)